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Background: The relationship between genetic factors and the development of cerebral palsy (CP) has recently
attracted much attention. Polymorphisms in the genes encoding proinflammatory cytokines have been shown to be
associated with susceptibility to perinatal brain injury and development of CP. Interleukin-6 (IL-6) is a proinflammatory
cytokine that plays a pivotal role in neonatal brain injury, but conflicting results have been reported regarding the
association between IL-6 single nucleotide polymorphisms (SNPs) and CP. The purpose of this study was to analyze IL-6
gene polymorphisms and protein expression and to explore the role of IL-6 in the Chinese CP population.
Methods: A total of 753 healthy controls and 713 CP patients were studied to detect the presence of five SNPs
(rs1800796, rs2069837, rs2066992, rs2069840, and rs10242595) in the IL-6 locus. Of these, 77 healthy controls and 87 CP
patients were selected for measurement of plasma IL-6 by Luminex assay. The SHEsis program was used to analyze the
genotyping data. For all comparisons; multiple testing on each individual SNP was corrected by the SNPSpD program.
Results: There were no differences in allele or genotype frequencies between the overall CP patients and controls
among the five genetic polymorphisms. However, subgroup analysis found significant sex-related differences in allele
and genotype frequencies. Differences were found between spastic CP and controls in males for rs2069837; between
CP with periventricular leukomalacia and controls in males for rs1800796 and rs2066992; and between term CP and
controls in males for rs2069837. Plasma IL-6 levels were higher in CP patients than in the controls, and this difference
was more robust in full-term male spastic CP patients. Furthermore, the genotype has an effect on IL-6 synthesis.
Conclusions: The influence of IL-6 gene polymorphisms on IL-6 synthesis and the susceptibility to CP is related to sex
and gestational age.
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Cerebral palsy (CP) is a group of non-progressive motor
impairment syndromes caused by lesions during early
brain development that often include cognitive deficits
and musculoskeletal dysfunction [1,2]. The prevalence of
CP – around 2 to 3 cases per 1,000 live births – has been
stable over the past 30 years [3]. CP has become the* Correspondence: xingqinghe@hotmail.com; changlian.zhu@neuro.gu.se
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unless otherwise stated.leading cause of childhood disability in both developing
and developed countries [4,5], but the vast majority of the
underlying pathogenic factors behind the development of
CP are still unknown. Risk factors for CP have been cate-
gorized as prenatal, perinatal, and postnatal, but the major-
ity of the risk factors – about 70% to 80% – occur
prenatally [6]. Prenatal inflammation, such as intrauterine
inflammation, is believed to be an important causal factor
of adverse neurological outcomes [7], and an abnormal
cytokine response has been suggested to be a common
pathway for inducing brain injury [8].
Interleukin-6 (IL-6) is a pro-inflammatory cytokine that
responds to intrauterine infection by inducing furtherhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Sample description for gene polymorphism
analysis
Characteristic CP cases Control
Total (%) M/F (n) Total (%) M/F (n)
Type of CP
Spastic CP 456 (64.0) 325/131 – –
Non-spastic CP 257 (36.0) 169/88 – –
Total 713 (100) 494/219 753 (100) 491/262
Gestational age
Term (≥37 weeks) 496 (69.6) 338/158 742 (98.5) 481/261
Preterm (<37 weeks) 217 (30.4) 156/61 11 (1.5) 10/1
Total 713 (100) 494/219 753 (100) 491/262
Birth weight
≥2,500 g 552 (77.4) 390/162 731 (97.1) 475/256
<2,500 g 161 (22.6) 104/57 22 (2.9) 16/6
Total 713 (100) 494/219 753 (100) 491/262
Birth asphyxia
No asphyxia 484 (67.9) 326/158 741 (98.4) 482/259
Asphyxia 229 (32.1) 168/61 12 (1.6) 9/3
Total 713 (100) 494/219 753 (100) 491/262
Complication
With PVL 75 (10.5) 56/19 – –
Without PVL 638 (89.5) 438/200 – –
With MR 274 (38.4) 185/89 – –
Without MR 439 (61.6) 309/130 – –
With HIE 342 (48.0) 245/97 – –
Without HIE 371 (52.0) 249/122 – –
Maternal factors
PROM 88 (12.3) 62/26 14 (1.9) 11/3
No PROM 625 (87.7) 432/193 739 (98.1) 480/259
TPL 57 (8.0) 42/15 23 (3.1) 17/6
No TPL 656 (92.0) 452/204 730 (96.9) 474/256
PIH 35 (4.9) 23/12 14 (1.9) 12/2
No PIH 678 (95.1) 471/207 739 (98.1) 479/260
CP, cerebral palsy; M, male; F, female; PVL, periventricular leukomalacia; MR,
mental retardation; HIE, hypoxic ischemic encephalopathy; PROM, premature
rupture of membrane; TPL, threatened premature labor; PIH,
pregnancy-induced hypertension.
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that IL-6 is linked to clinical chorioamnionitis and pre-
term birth and that there is a three-fold increased risk for
the development of periventricular leukomalacia (PVL) in
preterm infants [9,10]. The IL-6 single nucleotide poly-
morphism (SNP) rs1800795 (G-174C) was reported to be
associated with disabling brain injury but not cognitive
development in 148 children who were born at less than
32 weeks gestational age in the UK [9]. Additionally, a
population-based case-control study including 334,333
infants showed that rs1800795 is a risk factor for CP
among term and near-term infants who were born at
more than 36 weeks gestational age in the US [11,12].
However, with comparable gestational age distributions in
CP patients and control groups, conflicting results showed
no association between CP and rs1800795 in 144 very pre-
term infants who were born at less than 32 weeks gesta-
tional age in Croatia [13]. The conflicting results might be
based on differences in sample size or could indicate that
the effect of IL-6 gene function in the development of CP
might be influenced by ethnicity or gestational age. Based
on a replicate genetic study on SNPs from different regions
of the IL-6 gene, we have previously reported that the SNP
rs2069837 is associated with male spastic CP in the
Chinese Han population. To further confirm the risk
factors associated with SNPs and to validate the regulation
of IL-6 by the SNPs [10], we used a larger sample size to
analyze five polymorphisms from different regions of
the IL-6 gene and combined this with a plasma IL-6




The study population consisted of 713 CP patients (219
girls (30.7%) and 494 boys (69.3%) with a mean age ± SD
of 19.1 ± 14.9 months) chosen from centers for CP re-
habilitation in the Third Affiliated Hospital of Zheng-
zhou University and Zhengzhou Children’s Hospital
from 1 July 2010 to 31 May 2012 (Table 1). Of these, 87
CP patients (54 boys (62.1%) and 33 girls (37.9%) with a
mean age ± SD of 19.9 ± 14.1 months) were selected for
the serum IL-6 assay (Table 2). The 753 healthy control
participants (262 girls (34.8%) and 491 boys (65.2%) with
a mean age ± SD of 19.6 ± 18.5 months) were chosen
from the Child Healthcare Departments at the same
hospitals during the same period. Of these healthy con-
trols, 77 (63 boys (81.8%) and 14 girls (18.2%) with a
mean age ± SD of 19.8 ± 12.4 months) were selected for
the serum IL-6 assay. Blood samples were collected into
tubes containing EDTA by skilled nurses on the second
day of being hospitalized. Plasma was separated by cen-
trifugation (1,500 × g for 15 min) at room temperature
within 2 hours after being collected. DNA was obtainedfrom the remaining blood components from the same
sample. All the prepared samples were immediately
stored at −70°C. All subjects were Han Chinese from
the Henan Province, and written informed consent to
participate in this study was provided by the children’s
parents. Child neurologists diagnosed and classified the
CP by clinical examination or by using medical records,
including brain imaging, according to the guidelines
proposed by the “Surveillance of CP in Europe” network
[14]. Children in either the CP or control group with
myopathy or metabolic anomalies were excluded from
Table 2 Sample description for cytokine quantification
Characteristic CP cases Control
Total (%) M/F (n) Total (%) M/F (n)
Type of CP
CP with spastic 58 (68.2) 35/23 – –
CP without spastic 27 (31.8) 19/8 – –
Total 85 (100) 54/31 75 (100) 62/13
Gestational age
Term (≥37 weeks) 56 (65.9) 41/15 70 (93.3) 57/13
Preterm (<37 weeks) 29 (34.1) 13/16 5 (6.7) 5/0
Total 85 (100) 54/31 75 (100) 62/13
Birth weight
≥2,500 g 61 (71.8) 43/18 71 (94.7) 59/12
<2,500 g 24 (28.2) 11/13 4 (5.3) 3/1
Total 85 (100) 54/31 75 (100) 62/13
Birth asphyxia
No asphyxia 51 (60.0) 32/19 73 (97.3) 61/12
Asphyxia 34 (40.0) 22/12 2 (2.7) 1/1
Total 85 (100) 54/31 75 (100) 62/13
Complication
With PVL 17 (20.0) 11/6 – –
Without PVL 68 (80.0) 43/25 – –
With MR 62 (72.9) 37/25 – –
Without MR 23 (27.1) 17/6 – –
With HIE 31 (36.5) 20/11 – –
Without HIE 54 (63.5) 34/20 – –
Maternal factors
PROM 19 (22.4) 8/11 7 (9.3) 5/2
No PROM 66 (77.6) 46/20 68 (90.7) 57/11
TPL 20 (23.5) 15/5 15 (20.0) 11/4
No TPL 65 (76.5) 39/26 60 (80.0) 51/9
PIH 8 (9.4) 5/3 6 (8.0) 5/1
No PIH 77 (90.6) 49/28 69 (92.0) 57/12
CP, cerebral palsy; M, male; F, female; PVL, periventricular leukomalacia; MR,
mental retardation; HIE, hypoxic ischemic encephalopathy; PROM, premature
rupture of membrane; TPL, threatened premature labor; PIH,
pregnancy-induced hypertension.
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lected children ranged from 5 months to 36 months.
Children with cough, fever, acute respiratory illness, or
any other any indications of infection within the past
3 months were excluded. Because of the genetic factors
and familial factors that are associated with CP, we en-
sured that the controls had no familial relationships
with the patients and did not have neurological symp-
toms. Approval for the study was obtained from the eth-
ics committee of Zhengzhou University and the Medical
Academy of Henan Province (201201002) in accordance
with the Declaration of Helsinki.The database of medical records contains information
on CP risk factors, such as birth asphyxia, symptoms
concomitant with CP, such as mental retardation (MR),
neonatal complications, such as PVL, and on hypoxic-
ischemic encephalopathy (HIE). In addition, the records
contain information on maternal factors such as prema-
ture rupture of membrane (PROM), pregnancy-induced
hypertension (PIH), and threatening premature labor
(TPL). Asphyxia was diagnosed using the criteria of the
American Academy of Pediatrics and the American Col-
lege of Obstetricians and Gynecologists, and newborns
were included when at least three of the four criteria
were met [15]. MR was identified based on a score of
less than 70 on the Bayley Scales measurement of men-
tal development index [16]. PVL was defined as paren-
chymal densities or lucencies around the ventricles
during ultrasound examination of the head performed
any time after 14 days post-birth [17], and this was fur-
ther confirmed by MRI. Diagnosis of HIE required a
combination of parameters that are indicative of meta-
bolic acidosis within the first hours after birth. These in-
clude low umbilical cord blood pH (<7.0), a base deficit
of over 12 mEq/L, and evidence of a need for respiratory
support starting in the first minutes after birth with low
Apgar scores at and beyond 5 min after birth. The
diagnosis of PROM was based on pooling of amniotic
fluid in the vagina, amniotic fluid ferning patterns, and
a positive nitrazine test [18]. PIH was diagnosed and
classified according to the criteria recommended by
the American Congress of Obstetricians and Gynecol-
ogists, including a systolic blood pressure of 140 mmHg
or higher or a diastolic blood pressure of 90 mmHg or
higher on two occasions at least 6 h apart occurring
after 20 weeks of gestation in a pregnant woman with
previously normal blood pressure and without detect-
able urinary protein [19]. TPL was based on at least
one of the following having occurred during preg-
nancy: the mother was admitted to the hospital pre-
natally with an episode of TPL, the mother received
antenatal steroids or tocolytics, or a note was made on
the delivery room chart that there was a history of TPL
during the pregnancy [20].
Polymorphism selection
A total of five SNPs (rs1800796, rs2069837, rs2066992,
rs2069840, and rs10242595) of the IL-6 gene whose minor
allele frequencies in the Chinese Han population are
more than 0.1 were selected from the dbSNP database
(www.ncbi.nlm.nih.gov/SNP) and the hapmap human SNP
database (www.hapmap.org). All of rs2069837, rs2066992
in the second intron, and rs2069840 in the third intron
are tag SNPs. rs1800796 and rs10242595 are located in
the upstream and downstream regions of the IL-6 gene,
respectively.
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Genomic DNA was prepared from venous blood using the
AxyPrep Blood Genomic DNA Miniprep Kit (Axygen
Biosciences, Union City, CA, USA) according to the
manufacturer’s instructions. Probes and primers were
designed by the SEQUENOM online tools (https://
www.mysequenom.com) and the sequences are available
upon request. After the amplification of polymorphism-
spanning fragments by multiplex polymerase chain
reaction (PCR), the genotyping was performed with
the Sequenom MassARRAY SNP genotyping platform
(Sequenom, San Diego, CA, USA). The person who
analyzed the genotype results was blinded to the clinical
data.
IL-6 quantification
Blood samples were collected using EDTA as an anti-
coagulant. The samples were centrifuged at 1,500 × g for
15 min at room temperature, and plasma was aliquoted
and stored at −70°C. Before the assay, the frozen samples
were thawed completely at room temperature, mixed
well by vortexing, and centrifuged to remove precipi-
tated material. IL-6 was assayed together with IL-8,
IL-10, IL-17, TNF-α, or IFN-γ by using the Milliplex
Human Cytokine/Chemokine Kits (Millipore, Billerica,
MA, USA) according to the manufacturer’s instructions
on a Luminex 200IS System (Luminex Corporation,
Austin, TX, USA). Quality control was performed be-
tween the plates by using the two controls provided in
the kit and representative samples from both CP pa-
tients and controls run on all the plates. The assay was
completed on the same day by the same person. The
plate variation was 6.94% in this assay. IL-6 levels were
calculated using the Beadview software package (Upstate,
Temecula, CA, USA) and expressed as pg/mL. The detec-
tion limit for IL-6 was 0.3 pg/mL.
Statistical analysis
For gene analysis, the Hardy-Weinberg equilibrium
(HWE) test was performed on the allele and genotype
frequency analysis using the SHEsis online software
platform (http://analysis.bio-x.cn). Linkage disequilib-
rium was measured using standardized D’, and the dis-
crepancies in allele and genotype frequencies at single
loci between patients and controls were compared
using a Monte Carlo simulation strategy. The numbers
of observations for each haplotype were compared
using χ2 tests. The relative risk was approximated by
the estimate of the odds ratio (OR). All ORs were ad-
justed for age and sex using logistic regression models.
For each OR, a 95% confidence interval (CI) was calcu-
lated. For IL-6 cytokine analysis, the Student’s unpaired
t-test was used. Data groups with unequal variances
were analyzed using the Mann-Whitney U-test. Allreported P values were two-tailed and statistical sig-
nificance was set at P <0.05. The Statistical Package for
the Social Sciences (SPSS version 19.0) and Graphpad
Prism 6.0 software package (version 6.0 for Windows,
Graphpad, La Jolla, CA, USA) were used for all
statistical analyses. For all comparisons, multiple test-
ing on each individual SNP was corrected by the
SNPSpD program (http://gump.qimr.edu.au/general/daleN/
matSpD/), which is based on the linkage disequilibrium
information.Results
Overall analysis
The genotypic distribution of the five selected SNPs in the
controls was in HWE. There were no differences in allele
or genotype frequencies between the total population of
CP patients (n = 713) and total population of controls (n =
753) for any of the five genetic polymorphisms (Table 3).
Computation of D’ indicated a strong linkage disequilib-
rium between these SNP markers (D’ >0.8) (Table 4). A
haplotype analysis of all five SNPs between the CP and
control subjects was performed (those with a haplotype
frequency <0.03 were excluded from the analysis), and
three common haplotypes were built. No differences in the
haplotypes were found between CP cases and controls
(data not shown).Subgroup analysis
Subgroup analysis of SNPs was performed according to
sex, gestational age, birth weight, birth asphyxia, subtypes
of CP, pregnancy complications, and maternal factors. Sig-
nificant differences in allele frequencies were observed
between CP patients (n = 494) and controls (n = 491) in
males for rs2069837 (OR = 1.334, 95% CI = 1.073–1.659,
P = 0.009, P = 0.027 after SNPSpD correction) (Table 5),
but there were no differences in these SNP allele/genotype
frequencies between CP patients and controls in females
(data not shown).
Spastic CP was the main type of CP seen in this study
population. Differences in allele frequencies were observed
between spastic CP patients (n = 456) and controls (n =
753) for rs2069837, but the difference disappeared after
SNPSpD correction (data not shown). Further analysis ac-
cording to the sex of the CP patients revealed significant
differences in allele and genotype frequencies between
male spastic CP patients (n = 325) and controls (n = 491)
for rs1800796, rs2069837, and rs2066992, but the differ-
ences for rs1800796 and rs2066992 disappeared after
SNPSpD correction (Table 6), which was similar to our
previous analysis. Haplotype analysis for rs1800796,
rs2069837, and rs2066992 showed that the haplotypes
“CAT” and “GGG” (rs1800796, rs2069837, and rs2066992)
were strongly associated with male spastic CP patients
Table 3 Allele and genotype distribution of the five selected SNPs in cerebral palsy patients and controls
Group Allele frequency P value Genotype frequency P value Hardy-Weinberg equilibrium
rs1800796 C G C/C C/G G/G
Case 977 (0.690) 439 (0.310) 0.256 347 (0.490) 283 (0.400) 78 (0.110) 0.300 0.081
Control 992 (0.670) 488 (0.330) 334 (0.451) 324 (0.438) 82 (0.111) 0.797
rs2069837 A G A/A A/G G/G
Case 1138 (0.807) 272 (0.193) 0.062 469 (0.665) 200 (0.284) 36 (0.051) 0.144 0.018
Control 1134 (0.779) 322 (0.221) 448 (0.615) 238 (0.327) 42 (0.058) 0.169
rs2066992 G T G/G G/T T/T
Case 441 (0.311) 977 (0.689) 0.389 77 (0.109) 287 (0.405) 345 (0.487) 0.316 0.140
Control 483 (0.326) 999 (0.674) 77 (0.104) 329 (0.444) 335 (0.452) 0.775
rs2069840 C G C/C C/G G/G
Case 1300 (0.913) 124 (0.087) 0.503 591 (0.830) 118 (0.166) 3 (0.004) 0.787 0.258
Control 1346 (0.906) 140 (0.094) 607 (0.817) 132 (0.178) 4 (0.005) 0.265
rs10242595 A G A/A A/G G/G
Case 1255 (0.891) 153 (0.109) 0.435 560 (0.795) 135 (0.192) 9 (0.013) 0.498 0.789
Control 1279 (0.882) 171 (0.118) 569 (0.785) 141 (0.194) 15 (0.021) 0.079
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the analysis) (Table 7).
PVL is common in preterm brain injury and is related
to the development of CP. In this study, we found differ-
ences in genotype frequencies between CP patients with
PVL (n = 56) and controls (n = 491) in males at rs1800796
and rs2066992 (Table 8). The haplotype analysis of all five
analyzed SNPs did not show significant differences be-
tween CP patients with PVL and control subjects in either
males or females.
According to gestational age at birth, the CP patients
and controls were stratified as term or preterm CP cases.
A difference in allele and genotype frequencies for the
rs2069837 site was observed between term CP patients
(n = 338) and term controls (n = 491) in males (Table 9),
but no difference was found between preterm CP patients
(n = 156) and preterm controls in males or between term
and preterm CP patients in either males or females.
Differences in genotype frequencies were observed be-
tween CP patients with maternal PROM (n = 88) and con-
trols (n = 753) for rs2066992 and rs1800796 (Table 10).
Further analysis according to the sex of the CP patients







The standardized D’ values are shown above the diagonal, and the r2 values are shoPROM (n = 88) and controls (n = 491) in males for
rs2066992 and rs1800796, but the differences disappeared
after SNPSpD correction.
IL-6 quantification
The mean plasma IL-6 concentration was higher in the
CP patients than in the controls, and this difference was
more pronounced in males (Figure 1A). Subgroup ana-
lysis showed that the IL-6 level was higher in the spastic
CP group compared to the control group (Figure 1B).
Furthermore, the IL-6 level in the CP patients was re-
lated to gestational age and a significant increase was
seen in the full-term birth CP patients (Figure 1C).
However, the IL-6 level was not changed compared to
controls in the CP patients with PVL (Figure 1D). Fur-
ther statistical analyses stratified by birth weight, birth
asphyxia, MR, HIE, and maternal complications such as
PIH, TPL, and PROM were also performed but no dif-
ferences were found (data not shown). Furthermore, the
plasma IL-6 levels were different between CP patients
with genotypes CC and those with GG at rs1800796
(P = 0.033) (Figure 2A), and the plasma IL-6 levels of






wn below the diagonal.
Table 5 Allele and genotype distribution of the five selected SNPs in male cerebral palsy cases and controls
Group Allele frequency P value Genotype frequency P value Hardy-Weinberg equilibrium
rs1800796 C G C/C C/G G/G
Case 678 (0.690) 304 (0.310) 0.092 242 (0.493) 194 (0.395) 55 (0.112) 0.113 0.093
Control 631 (0.655) 333 (0.345) 206 (0.427) 219 (0.454) 57 (0.118) 0.917
rs2069837 A G A/A A/G G/G
Case 790 (0.808) 188 (0.192) 0.009a 326 (0.667) 138 (0.282) 25 (0.051) 0.041 0.044
Control 718 (0.759) 228 (0.241) 279 (0.590) 160 (0.338) 34 (0.072) 0.101
rs2066992 G T G/G G/T T/T
Case 303 (0.309) 677 (0.691) 0.119 53 (0.108) 197 (0.402) 240 (0.490) 0.159 0.193
Control 330 (0.342) 634 (0.658) 55 (0.114) 220 (0.456) 207 (0.429) 0.764
rs2069840 C G C/C C/G G/G
Case 901 (0.914) 85 (0.086) 0.646 411 (0.834) 79 (0.160) 3 (0.006) 0.742 0.704
Control 877 (0.908) 89 (0.092) 396 (0.820) 85 (0.176) 2 (0.004) 0.253
rs10242595 A G A/A A/G G/G
Case 870 (0.895) 102 (0.105) 0.304 391 (0.805) 88 (0.181) 7 (0.014) 0.578 0.426
Control 838 (0.880) 114 (0.120) 372 (0.782) 94 (0.197) 10 (0.021) 0.168
aAfter the SNPSpD correction, the P value is 0.027.
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tients were higher than in their respective controls.
Therefore, we have sufficient evidence to assume that
there is a positive association of the IL-6 gene with the
etiology of CP.Table 6 Allele and genotype distributions of the SNPs in male
Group Allele frequency P value Genotype
rs1800796 C G C/C
Spastic 458 (0.709) 188 (0.291) 0.022 169 (0.523
Non-spastic 220 (0.655) 116 (0.345) 0.995 73 (0.435)
Control 631 (0.655) 333 (0.345) 206 (0.427
rs2069837 A G A/A
Spastic 524 (0.816) 118 (0.184) 0.007a 220 (0.685
Non-spastic 266 (0.792) 70 (0.208) 0.223 106 (0.631
Control 718 (0.759) 228 (0.241) 279 (0.590
rs2066992 G T G/G
Spastic 189 (0.293) 455 (0.707) 0.040 34 (0.106)
Non-spastic 114 (0.339) 222 (0.661) 0.919 19 (0.113)
Control 330 (0.342) 634 (0.658) 55 (0.114)
rs2069840 C G C/C
Spastic 599 (0.924) 49 (0.076) 0.245 276 (0.852
Non-spastic 302 (0.893) 36 (0.107) 0.440 135 (0.799
Control 877 (0.908) 89 (0.092) 396 (0.820
rs10242595 A G A/A
Spastic 575 (0.901) 63 (0.099) 0.192 261 (0.818
Non-spastic 295 (0.883) 39 (0.117) 0.885 130 (0.778
Control 838 (0.880) 114 (0.120) 372 (0.782
aAfter the SNPSpD correction, the P value is 0.021.Discussion
IL-6 is a proinflammatory cytokine that plays a key role in
systemic inflammatory processes and has been identified
as an important mediator of prenatal inflammation and
CP. Clinical studies suggest that preterm neonates born tospastic cerebral palsy patients and controls
frequency P value Hardy-Weinberg equilibrium
C/G G/G
) 120 (0.372) 34 (0.105) 0.027 0.073
74 (0.440) 21 (0.125) 0.944 0.739
) 219 (0.454) 57 (0.118) 0.917
A/G G/G
) 84 (0.262) 17 (0.053) 0.024 0.022
) 54 (0.321) 8 (0.048) 0.457 0.740
) 160 (0.338) 34 (0.072) 0.101
G/T T/T
121 (0.376) 167 (0.519) 0.041 0.092
76 (0.452) 73 (0.435) 0.994 0.907
220 (0.456) 207 (0.429) 0.764
C/G G/G
) 47 (0.145) 1 (0.003) 0.489 0.498
) 32 (0.189) 2 (0.012) 0.496 0.947
) 85 (0.176) 2 (0.004) 0.253
A/G G/G
) 53 (0.166) 5 (0.016) 0.444 0.235
) 35 (0.210) 2 (0.012) 0.729 0.835
) 94 (0.197) 10 (0.021) 0.168
Table 7 Estimated IL-6 haplotype frequencies
Haplotype Case (frequency) Control (frequency) P value OR [95% CI]
CAT 446.99 (0.705) 586.16 (0.634) 0.011a 1.331 [1.068–1.659]
GGG 113.50 (0.179) 202.19 (0.219) 0.039 0.764 [0.591–0.987]
Global results 0.037
Loci chosen for haplotype analysis: rs1800796, rs2069837, and rs2066992.
Haplotype frequency <0.03 in both controls and cases have been dropped.
aAfter Bonferroni correction the P value is 0.033.
OR, odds ratio; CI, confidence interval.
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http://www.jneuroinflammation.com/content/11/1/100mothers with elevated IL-6 levels in the amniotic fluid are
at increased risk for the subsequent development of PVL
and CP [21], and CP patients show higher IL-6 levels in
the cerebral spinal fluid [22]. Furthermore, infection has
been shown to be an independent risk factor for spastic
hemiplegia CP in infants born at term [23] and chorioam-
nionitis has been shown to be the most common cause
of spastic quadriplegia CP [24]. In this study, we found
that the plasma IL-6 levels were higher in CP patients
than in controls and that IL-6 levels increased dramatic-
ally in spastic CP patients, which has not previously
been reported. Overall, the findings from previous stud-
ies and our current work suggest that IL-6 is strongly
associated with CP. Although we could not confirmTable 8 Allele and genotype distributions of the SNPs in male
periventricular leukomalacia (PVL)
Group Allele frequency P value Genotype
rs1800796 C G C/C
CP + PVL 80 (0.714) 32 (0.286) 0.206 33 (0.589)
CP − PVL 598 (0.687) 272 (0.331) 0.136 209 (0.480)
Control 631 (0.655) 333 (0.345) 206 (0.427)
rs2069837 A G A/A
CP + PVL 91 (0.812) 21 (0.188) 0.207 39 (0.696)
CP − PVL 699 (0.807) 167 (0.193) 0.013a 287 (0.663)
Control 718 (0.759) 228 (0.241) 279 (0.590)
rs2066992 G T G/G
CP + PVL 32 (0.286) 80 (0.714) 0.230 9 (0.161)
CP − PVL 271 (0.312) 597 (0.688) 0.171 44 (0.101)
Control 330 (0.342) 634 (0.658) 55 (0.114)
rs2069840 C G C/C
CP + PVL 105 (0.938) 7 (0.062) 0.554 49 (0.875)
CP − PVL 796 (0.911) 78 (0.890) 0.830 362 (0.828)
Control 877 (0.908) 89 (0.092) 396 (0.820)
rs10242595 A G A/A
CP + PVL 99 (0.900) 11 (0.100) 0.543 45 (0.818)
CP − PVL 771 (0.894) 91 (0.106) 0.341 346 (0.803)
Control 838 (0.880) 114 (0.120) 372 (0.782)
aAfter the SNPSpD correction, the P value is 0.039.
bAfter the SNPSpD correction, the P value is 0.042.
cAfter the SNPSpD correction, the P value is 0.039.whether the elevation of IL-6 levels is a recurrent or
persistent issue that occurs after the event that led to
the development of CP or if it is a transient effect during
the late stage of CP; such increases might help to identify
infants that could possibly benefit from later therapeutic
interventions.
Genetic regulation of inflammation is an important
biological risk factor that might contribute to the risk of
developing CP [13]. The promoter region polymorphism
rs1800795 (G-174C) in the IL-6 gene has been associ-
ated with CP in populations from both Australia [8] and
California [12]. The variant C allele of rs1800795 (G-174C)
has been shown to markedly increase the risk of hemiplegic
CP and quadriplegic CP in infants [8], and the CC genotypecerebral palsy (CP) patients with or without
frequency P value Hardy-Weinberg equilibrium
C/G G/G
14 (0.250) 9 (0.161) 0.014b 0.004
180 (0.414) 46 (0.106) 0.272 0.437
219 (0.454) 57 (0.118) 0.917
A/G G/G
13 (0.232) 4 (0.071) 0.263 0.075
125 (0.289) 21 (0.048) 0.057 0.131
160 (0.338) 34 (0.072) 0.101
G/T T/T
14 (0.250) 33 (0.589) 0.013c 0.004
183 (0.422) 207 (0.477) 0.348 0.705
220 (0.456) 207 (0.429) 0.764
C/G G/G
7 (0.125) 0 (0.000) 0.554 0.618
72 (0.165) 3 (0.007) 0.778 0.777
85 (0.176) 2 (0.004) 0.253
A/G G/G
9 (0.164) 1 (0.018) 0.821 0.500
79 (0.183) 6 (0.014) 0.603 0.542
94 (0.197) 10 (0.021) 0.168
Table 9 Allele and genotype distributions of the SNPs in male term cerebral palsy patients and controls
Group Allele frequency P value Genotype frequency P value Hardy-Weinberg equilibrium
rs1800796 C G C/C C/G G/G
Case 463 (0.689) 209 (0.311) 0.137 162 (0.482) 139 (0.414) 35 (0.104) 0.282 0.525
Control 617 (0.654) 327 (0.346) 20 (0.426) 215 (0.456) 56 (0.119) 0.897
rs2069837 A G A/A A/G G/G
Case 540 (0.811) 126 (0.189) 0.012a 220 (0.661) 100 (0.300) 13 (0.039) 0.046 0.699
Control 702 (0.758) 224 (0.242) 272 (0.587) 158 (0.341) 33 (0.071) 0.134
rs2066992 G T G/G G/T T/T
Case 209 (0.312) 461 (0.688) 0.203 33 (0.099) 143 (0.427) 159 (0.475) 0.430 0.918
Control 323 (0.342) 621 (0.658) 54 (0.114) 215 (0.456) 203 (0.430) 0.797
rs2069840 C G C/C C/G G/G
Case 610 (0.905) 64 (0.095) 0.838 276 (0.819) 58 (0.172) 3 (0.009) 0.701 0.980
Control 859 (0.908) 87 (0.092) 388 (0.820) 83 (0.175) 2 (0.004) 0.271
rs10242595 A G A/A A/G G/G
Case 595 (0.891) 73 (0.109) 0.544 266 (0.796) 63 (0.189) 5 (0.015) 0.769 0.570
Control 821 (0.881) 111 (0.119) 365 (0.783) 91 (0.195) 10 (0.021) 0.134
aAfter the SNPSpD correction, the P value is 0.036.
Table 10 Allele and genotype distributions of the SNPs in patients with or without maternal premature rupture of
membrane (PROM)
Group Allele frequency P value Genotype frequency P value Hardy-Weinberg equilibrium
rs1800796 C G C/C C/G G/G
CP + PROM 121 (0.695) 53 (0.305) 0.504 49 (0.563) 23 (0.264) 15 (0.172) 0.006a 0.001
CP − PROM 856 (0.689) 386 (0.311) 0.292 298 (0.480) 260 (0.419) 63 (0.101) 0.560 0.572
Control 992 (0.670) 488 (0.330) 334 (0.451) 324 (0.438) 82 (0.111) 0.011*b 0.797
rs2069837 A G A/A A/G G/G
CP + PROM 145 (0.824) 31 (0.176) 0.171 62 (0.705) 21 (0.239) 5 (0.057) 0.231 0.095
CP − PROM 993 (0.805) 241 (0.195) 0.101 407 (0.660) 179 (0.290) 31 (0.050) 0.243 0.056
Control 1134 (0.779) 322 (0.221) 448 (0.615) 238 (0.327) 42 (0.058) 0.169
rs2066992 G T G/G G/T T/T
CP + PROM 54 (0.307) 122 (0.693) 0.609 15 (0.170) 24 (0.273) 49 (0.557) 0.005c 0.001
CP − PROM 387 (0.312) 855 (0.688) 0.425 62 (0.100) 263 (0.424) 296 (0.477) 0.663 0.750
Control 483 (0.326) 999 (0.674) 77 (0.104) 329 (0.444) 335 (0.452) 0.012*d 0.775
rs2069840 C G C/C C/G G/G
CP + PROM 163 (0.926) 13 (0.0734 0.377 75 (0.852) 13 (0.148) 0 (0.000) 0.607 0.454
CP − PROM 1137 (0.911) 111 (0.089) 0.635 516 (0.827) 105 (0.168) 3 (0.005) 0.889 0.339
Control 1346 (0.906) 140 (0.094) 607 (0.817) 132 (0.178) 4 (0.005) 0.265
rs10242595 A G A/A A/G G/G
CP + PROM 153 (0.879) 21 (0.121) 0.915 68 (0.782) 17 (0.195) 2 (0.023) 0.990 0.459
CP − PROM 1102 (0.893) 132 (0.107) 0.371 492 (0.797) 118 (0.191) 7 (0.011) 0.395 0.980
Control 1279 (0.882) 171 (0.118) 569 (0.785) 141 (0.194) 15 (0.021) 0.079
*Comparison between total CP patients with maternal PROM and without PROM.
aAfter the SNPSpD correction, the P value is 0.0018.
bAfter the SNPSpD correction, the P value is 0.033.
cAfter the SNPSpD correction, the P value is 0.015.
dAfter the SNPSpD correction, the P value is 0.036.
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Figure 1 Plasma IL-6 concentrations in CP patients and controls. (A) Distribution of plasma IL-6 concentrations between total CP patients
(85 patients) and total controls (75 participants) and between subgroups analyzed by sex. (B) Plasma IL-6 concentrations among spastic CP
patients (58 patients), non-spastic CP patients (27 patients), and controls. (C) Plasma concentrations among term CP patients (56 patients), preterm
CP patients (29 patients), and controls. (D) Plasma IL-6 concentrations among CP patients with PVL (17 patients), CP patients without PVL (68
patients), and controls. Each dot represents one patient and each bar represents the mean value. *P <0.05; Mann-Whitney U-test. CP, cerebral
palsy; PVL, periventricular leukomalacia.
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http://www.jneuroinflammation.com/content/11/1/100of the 174C/G variation is related to higher levels of IL-
6 compared to the GG genotype [25].
Studies of IL-6 polymorphisms have mainly focused on
rs1800795 [8,12], but this polymorphism is absent in the
Han Chinese population [26]. The SNPs rs1800796,Figure 2 Comparison of genotypes and plasma IL-6 levels in CP patie
comparison at rs2069837. (C) The comparison at rs2066992. Each dot repre
Mann-Whitney U-test. CP, cerebral palsy.rs2069837, and rs10242595 have all been reported to be
associated with Alzheimer’s disease and ischemic stroke
[27-30], and the rs2069840 SNP has been shown to be
associated with systemic sclerosis [31]. The common
haplotype tagged by the SNP rs1800796 (C-572G) hasnts and controls. (A) The comparison at rs1800796. (B) The
sents one patient and each bar represents the mean value. *P <0.05;
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http://www.jneuroinflammation.com/content/11/1/100been shown to be associated with an increased risk of
brain infarct in elderly subjects in a cardiovascular
health study [32]. Even though these SNPs were associ-
ated with neurological disease in adults, so far there has
been no evidence showing an association with CP. This
study has, for the first time, shown that associations be-
tween IL-6 polymorphisms and CP are related to sex,
PVL, gestational age, and the clinical subtype of CP.
The rs2069837 SNP is associated with male spastic CP
patients born at full term, and the genotypes of
rs1800796 and rs2066992 are associated with male CP
patients with PVL.
The genotypes produced from rs1800796 and rs2066992
SNPs, however, showed deviation from HWE in CP pa-
tients with PVL. Deviations from HWE could point to a
sampling bias, mistyping of genotypes, or spurious gene
associations after population stratification [33]. We care-
fully re-analyzed the data based on the reasons mentioned
above and found that all of the controls were in HWE. As
Esser suggested, if only the genotype distribution of the
patient group shows deviation from HWE, this might pro-
vide additional support for an association between the
marker locus with the disease in question [33]. Therefore,
our study showed that the genotypes produced from the
two SNPs (rs1800796 and rs2066992) are more likely as-
sociated with male CP patients with PVL. On the other
hand, we cannot exclude the potential problem of a small
sample size (n = 56) after population stratification.
In addition to changes in SNP frequency, we also mea-
sured IL-6 levels directly and found that in CP patients the
CC genotype of rs1800796 (C-572G) has an effect on
serum levels of IL-6 compared to the GG genotype. This is
similar to what has been seen in trauma patients carrying
the −572 C allele or −572 G allele [34]. This suggests that
the G allele of rs1800796 could reduce transcriptional ac-
tivity of the IL-6 promoter. We also found that the plasma
IL-6 levels of genotype CC at rs1800796, AA at rs2069837,
and TT at rs2066992 in CP patients were higher than their
respective controls. We speculate that the genetic variation
might enhance or weaken the inflammatory response to
some extent during the pathogenic process of CP, or it
might influence the interaction between genetic factors
and the environment. It seems that the C allele of
rs1800796, the A allele of rs2069837, and the T allele of
rs2066992 might be risk factors for CP. This must be fur-
ther confirmed with even larger samples.
In this study population, 69.3% (494/713) of the CP
patients were males, and this proportion is in accord-
ance with reports from other nations [35-38]. This sex-
related difference has also been noticed in in vitro and
in vivo models of cerebral ischemia and neuronal injury
[39]. However, even though sex hormones, such as estro-
gens, protect against brain injury [40], the circulating hor-
mone levels cannot completely account for sex differencesin the CP patients or in the developing brain [41]. This
could be related to genetic background since it has been
reported that female-derived neurons (XX) have a survival
advantage compared with male-derived neurons (XY) [42].
PROM has been associated with increased risk for intra-
uterine infection and clinical chorioamnionitis [43,44],
and it has been observed that infants born after PROM
are at increased risk of white matter injury and subsequent
CP diagnosis [45,46]. In our study, we found that the ge-
notypes of SNPs rs1800796 and rs2066992 are associated
with CP and that this association is more robust in CP pa-
tients with maternal PROM. This finding suggests that
maternal infections can be an up-stream causative factor
that contributes to CP.
In summary, our study suggests that IL-6 participates
in the pathogenesis of CP in a sex-related manner and
that IL-6 gene polymorphisms are risk markers for male
term infants and might be related to the development of
PVL in male CP patients.
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